Novavax, Inc. (LON:0A3S)

Market Cap	957.81M
Revenue (ttm)	787.36M
Net Income (ttm)	308.62M
Shares Out	n/a
EPS (ttm)	1.86
PE Ratio	3.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,948
Average Volume	84,447
Open	7.83
Previous Close	8.06
Day's Range	7.59 - 7.90
52-Week Range	5.02 - 11.78
Beta	2.75
RSI	36.25
Earnings Date	Nov 6, 2025

About Novavax

Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 952
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A3S

Financial Performance

In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.

Financial numbers in USD